A phase I/IIa Study of the CD38 Antibody MOR202 in Combination With Pomalidomide or Lenalidomide in Patients With Relapsed or Refractory Multiple Myeloma
暂无分享，去创建一个
H. Goldschmidt | H. Einsele | M. Winderlich | C. Peschel | H. Agis | M. Chatterjee | M. Engelhardt | A. Günther | M. Raab | K. Weisel | B. Ferstl | I. Blau | C. Röllig | Dominika Weinelt | R. Boxhammer | Tiantom Jarutat